SEC Form 4 · accession 0001209191-18-023804
Eiger BioPharmaceuticals, Inc. · EIGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joanne Quan
Officer — Chief Medical Officer
Period of report
Apr 2, 2018
Accepted (ET)
Apr 4, 2018 · 5:18 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001305253
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 2, 2018 | M | 4,000 | $2.06 | A | 4,000 | D | |
| Common Stock | Apr 2, 2018 | S | 4,000 | $10.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $2.06 | Apr 2, 2018 | M | 4,000 | D | — | Sep 22, 2025 | Common Stock | 4,000 | 22,256 | D |
Explanation of responses
- F125% of the option vested on April 14, 2016 and the remaining shares vest in successive equal monthly installments for the subsequent 36 months subject to Reporting Person's continuous service status as of each such date.